Contraceptive efficacy and global licensing of 52 mg levonorgestrel intrauterine devices: does a Mirena last longer in New York than York?

BMJ Sex Reprod Health. 2024 Jan 9;50(1):4-6. doi: 10.1136/bmjsrh-2023-201937.

Authors

Zachary Nash^{1

2}, Annette Thwaites^{2

3}

Affiliations

¹ Reproductive Medicine Unit, University College London Hospital, London, UK [email protected].
² EGA Institute for Women's Health, University College London, London, UK.
³ Sexual and Reproductive Health, King's College Hospital NHS Trust, London, UK.

PMID: 37648421
DOI: 10.1136/bmjsrh-2023-201937

No abstract available

Keywords: contraceptive devices, female; contraceptive effectiveness; intrauterine devices, medicated.

Publication types

Editorial

MeSH terms

Contraception
Contraceptive Agents, Female* / therapeutic use
Female
Humans
Levonorgestrel* / therapeutic use
New York

Substances

Levonorgestrel
Contraceptive Agents, Female